NATURES SUNSHINE PRODUCTS INC NATR
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
6/9
Piotroski F — financial health
5.82
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $480.1M | $19.5M | $347.7M | $28.8M | $161.6M |
| 2024 | $454.4M | $7.7M | $324.7M | $14.3M | $161.0M |
| 2023 | $445.3M | $15.1M | $321.1M | $30.7M | $159.5M |
| 2022 | $421.9M | -$390,000 | $299.8M | -$6.9M | $147.0M |
| 2021 | $444.1M | — | $328.6M | $27.9M | $161.4M |
| 2020 | $385.2M | — | $283.9M | $32.8M | $157.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Herbert Kevin R. | EVP & President, North America | 2026-06-12 | Sell | 1,134 | $20.63 |
| Herbert Kevin R. | EVP & President, North America | 2026-06-12 | Sell | 866 | $20.75 |
| Yates Bryant J | EVP & President, Europe | 2026-06-05 | Sell | 11,968 | $19.90 |
| Norman Daniel C | EVP & President, Asia | 2026-06-01 | Sell | 9,713 | $20.64 |
| Brower Nathan G | EVP, General Counsel | 2026-05-21 | Sell | 12,015 | $21.84 |
| Fasching Steven J. | director | 2026-05-15 | Grant | 4,500 | — |
| Wissmiller Heidi | director | 2026-05-15 | Grant | 4,500 | — |
| Yates Bryant J | EVP & President, Europe | 2026-05-15 | Grant | 8,753 | — |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 5.82 (safe)
- Working capital / assets 0.384
- Retained earnings / assets 0.295
- EBIT / assets 0.095
- Equity / liabilities 1.622
Source: SEC EDGAR filings · CIK 0000275053 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.